Extended Data Table 5 Injection site reactions in the long-acting therapy group from baseline to week 96

From: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

  1. *Number of participants with injection site reactions, by maximum grade. Shown is the proportion of participants with reaction of that grade out of the total 255 participants in the long-acting group.
Back to article page